DEVELOPING UNIQUE Allosteric modulators of integrins for Triple Negative Breast Cancer
AVIPERO has unique Platform technology with multiple applications/indications.
AVIPERO is a strong team with track record in drug development in cancer. At Avipero we aspire to revolutionize the treatment of malignant and degenerative diseases worldwide. We are dedicated to the study of breast cancer, our pharmaceutical research company prioritizes the development of a non-destructive cure for this metastatic disease.